Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly/Amylin submit exenatide

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly/Amylin plan to position their type 2 diabetes agent exenatide for use in patients not achieving goal on oral agents; an NDA for the first-in-class incretin mimetic was submitted June 30. "The initial target population for exenatide does not include patients on insulin," Lilly says. Based on exenatide's novel mechanism, the firms are highlighting its potential as an insulin alternative "that carries a lower risk of hypoglycemia with no weight gain." A National Institutes of Health-sponsored study of exenatide in type 1 diabetes is underway. "The results of that [20-month] exploratory study will determine our next steps in the type 1 diabetes arena," Lilly says...

You may also be interested in...

Approvals In Brief

Lilly/Amylin Byetta clears FDA as first incretin mimetic; GSK readies Boostrix launch following May 3 BLA approval. GlaxoSmithKline’s dopamine agonist Requip (ropinirole) is approved May 4 as the first treatment for restless legs syndrome. More FDA approvals in brief

Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005

Highlights of NME class of 2005 could be advances in diabetes, with Lilly/Amylin’s exenatide and Amylin’s Symlin currently being reviewed and Pfizer’s inhaled insulin Exubera slated for filing early in the year. Other major pending NMEs include J&J’s dapoxetine for premature ejaculation and Solvay’s irritable bowel syndrome agent Calmactin (cilansetron)

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts